At the AACE 2017 Annual Congress, Dr. Jothydev presented two of their original research studies conducted at Jothydev�s Diabetes Research Center, Trivandrum, Kerala. One of the papers which gained much attraction at the AACE was on the benefits of early initiation of insulin therapy in newly onset Type 2 diabetes patients. From their 12 year long study, it was observed that if the patients were initiated early enough on small doses of insulin soon after their diabetes diagnosis, they did not develop diabetes related co-morbidities even after several years of disease onset. In diabetes, at the time of diagnosis itself, there is almost 70% decrease in insulin production. Early initiation of insulin therapy is often much delayed mainly due to a negative mindset of the patient towards starting insulin injections. Once the patient is able to successfully overcome this fear, the disease can be well controlled with minimal doses of insulin and without diabetes-related complications, even after 10 or 20 years of the onset of diabetes. The study also reveals that unless managed early, diabetes may become uncontrollable in later stages and the doses of medications will have to be increased all of which pronouncedly increases the diabetes treatment costs that could be unbearable to a common man. In another study presented at AACE by Dr Jothydev, when patients were started on Liraglutide injections soon after their diabetes onset, a complete or near complete remission of diabetes was achieved by a significant number of patients (70%). Dr Arun Shankar, Gopika Krishnan, Sunitha Jothydev, Dr Ashwin David Ashok and Lakshmy Ramachandran were part of the original research from Jothydev�s Diabetes Research Centre, Trivandrum.